Metabolic profiles in urine reflect nephrotoxicity of sirolimus and cyclosporine following rat kidney transplantation

Nephron - Experimental Nephrology

Volumn 111, Issue 4, 2009, Pages

  Schmitz, Volker ^a,c   Klawitter, Jost ^b,c,e   Bendrick Peart, Jamie ^e   Schoening, Wenzel ^a   Puhl, Gero ^a   Haschke, Manuel ^c   Klawitter, Jelena ^b,c   Consoer, Jeff ^c   Rivard, Christopher J ^d   Chan, Laurence ^d   Tran, Zung V ^d   Leibfritz, Dieter ^b   Christians, Uwe ^c,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e Eurofins Medinet Inc   (Germany)

Author keywords

Cyclosporine; Ischemia reperfusion; Kidney transplantation; Nephrotoxicity; Sirolimus; Urine metabolic profiles

Indexed keywords

2 OXOGLUTARIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CITRIC ACID; CREATINE; CREATININE; CYCLOSPORIN A; ISOPROSTANE DERIVATIVE; RAPAMYCIN; SUCCINIC ACID; TAURINE; TRIMETHYLAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CELL FUNCTION; CELL METABOLISM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MARKER; ENERGY METABOLISM; GRAFT RECIPIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOSUPPRESSIVE TREATMENT; INBRED STRAIN; KIDNEY CELL; KIDNEY CONCENTRATING CAPACITY; KIDNEY ISCHEMIA; KIDNEY METABOLISM; KIDNEY PARENCHYMA; KIDNEY PERFUSION; KIDNEY TRANSPLANTATION; LEWIS RAT; MALE; MASS SPECTROMETRY; METABOLIC PARAMETERS; METABOLITE; MONOTHERAPY; NEPHRECTOMY; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; URINALYSIS;

ANIMALS; BIOLOGICAL MARKERS; CYCLOSPORINE; KIDNEY TRANSPLANTATION; MALE; METABOLOME; RATS; RATS, INBRED LEW; SIROLIMUS;

EID: 67649087986     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209208     Document Type: Article

References (47)

1. Campistol JM, Grinyo JM: Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity. Transplantation 2001; 71(suppl 11):SS42-SS51.
2. Morozumi K, Takeda A, Uchida K, Mihatsch MJ: Cyclosporine nephrotoxicity: how does it affect renal allograft function and transplant morphology? Transplant Proc 2004; 36(suppl 2):251S-256S.
3. Meier-Kriesche HU, Li S, Gruessner RW, et al: Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111-1131.
4. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP: Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74:1560-1567.
5. Groth CG, Backman L, Morales JM, et al: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:1036-1042.
6. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72:777-786.
7. Morales JM, Campistol JM, Kreis H, et al: Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients. Transplant Proc 2005; 37: 693-696.
8. Podder H, Stepkowski SM, Napoli KL, et al: Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059-1071.
9. Serkova N, Jacobsen W, Niemann CU, et al: Sirolimus, but not the structurally relatedRAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol 2001; 133: 875-885.
10. Andoh TF, Lindsley J, Franceschini N, Bennett WM: Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62: 311-316.
11. Nielsen FT, Ottosen P, Starklint H, Diepe rink H: Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat. Nephrol Dial Transplant 2003; 18: 491-496.
12. Christians U, Schmitz V, Haschke M: Functional interaction between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol 2005; 1: 641-654.
13. Serino F, Grevel J, Napoli KL, Kahan BD, Strobel HW: Oxygen radical formation by the cytochrome P450 system as a cellular mechanism for cyclosporine toxicity. Transplant Proc 1994; 26: 2916-2917.
14. Davis C: Sirolimus delays renal allograft recovery. Am J Transplant 2003; 3: 363-365.
15. Lieberthal W, Fuhro R, Andry CC, et al: Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001; 281:F693-F706.
16. McTaggart RA, Gottlieb D, Brooks J, et al: Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3: 416-423.
17. Wishart DS: Metabolomics: the principles and potential applications to transplantation. Am J Transplant 2005; 5: 2814-2820.
18. Holmes E, Bonner FW, Nicholson JK: 1H NMR spectroscopic and histopathological studies on propyleneimine-induced renal papillary necrosis in the rat and the multimammate desert mouse (Mastomys natalensis). Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1997; 116: 125-134.
19. Robertson DG, Reily MD, Sigler RE, Wells DF, Paterson DA, Braden TK: Metabonomics: evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol Sci 2000; 57:326-337.
20. de Boer J, Smits JM, De Meester J, et al: A randomized multicenter study on kidney preservation comparing HTK with UW. Transplant Proc 1999; 31: 2065-2066.
21. Ma Y, Kobayashi T, Kuzuya T, et al: Is absorption profile of cyclosporine really important for effective immunosuppression? Biol Pharm Bull 2006; 29: 336-342.
22. Christians U, Jacobsen W, Serkova N, et al: Automated, fast and sensitive quantification of drugs in blood by liquid chromatographymass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl 2000; 748: 41-53.
23. 2t -isoprostane in human urine and plasma. Clin Chem 2007; 53: 489-497.
24. Klawitter J, Schmitz V, Klawitter J, Leibfritz D, Christians U: Development and validation of an assay for the quantification of 11 nucleotides using LC/LC-electrospray ionization- MS. Anal Biochem 2007; 365: 230-239.
25. Samuta T, Becker GL, Pohorecki R, Armstrong K, Landers DF: Effects of isoflurane dose, duration of anoxia, and reoxygenation on isoflurane's preservation of energy balance in anoxic isolated hepatocytes. Anesth Analg 1993; 77: 38-43.
26. Schnackenberg LK, Sun J, Espandiari P, Holland RD, Hanig J, Beger RD: Metabonomics evaluations of age-related changes in the urinary compositions of male Sprague Dawley rats and effects of data normalization methods on statistical and quantitative analysis. BMC Bioinformatics 2007; 8(suppl 7):S3.
27. Rosner B: Fundamentals of Biostatistics, ed 6. Pacific Grove, Duxbury Press, 2006.
28. Neild GH, Foxall PJ, Lindon JC, Holmes EC, Nicholson JK: Uroscopy in the 21st century: high-field NMR spectroscopy. Nephrol Dial Transplant 1997; 12: 404-417.
29. Brook NR, Waller JR, Bicknell GR, Nicholson ML: Cyclosporine and rapamycin act in a synergistic and dose-dependent manner in a model of immunosuppressant-induced kidney damage. Transplant Proc 2005; 37: 837-838.
30. Nashan B: Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors. Transpl Int 2004; 17: 279-285.
31. Lenz EM, Bright J, Knight R, Wilson ID, Major H: Cyclosporin A-induced changes in endogenous metabolites in rat urine: a metabonomic investigation using high field 1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. J Pharm Biomed Anal 2004; 35: 599-608.
32. Wang C, Salahudeen AK: Cyclosporine nephrotoxicity: attenuation by an antioxidant-inhibitor of lipid peroxidation in vitro and in vivo. Transplantation 1994; 58: 940-946.
33. Wolf A, Trendelenburg CF, Diez-Fernandez C, et al: Cyclosporine A-induced oxidative stress in rat hepatocytes. J Pharmacol Exp Ther 1997; 280: 1328-1334.
34. Christians U, Gottschalk S, Miljus J, et al: Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors. Br J Pharmacol 2004; 143: 388-396.
35. Schmitz V, Klawitter J, Bendrick-Peart J, et al: Impact of organ preservation using HTK for graft flush and subsequent storage in UW in rat kidney transplantation. Eur Surg Res 2006; 38: 388-398.
36. Lawson JA, Rokach J, FitzGerald GA: Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 1999; 274: 24441-24444.
37. Serkova N, Klawitter J, Niemann CU: Organspecific response to inhibition of mitochondrial metabolism by cyclosporine in the rat.Transpl Int 2003; 16: 748-755.
38. Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S: Sirolimus delays recovery of rat kidney transplants after ischemia- reperfusion injury. Transplantation 2003; 76: 1594-1599.
39. Buss WC, Griffey R: Dissociation of decreases in renal cellular energetics and recovery of renal microsomal translation during chronic cyclosporine A administration. Biochem Pharmacol 1991; 42: 71-76.
40. Chan L, Shapiro JI: Magnetic resonance study of renal transplantation. Ren Physiol Biochem 1989; 12: 181-190.
41. Bairaktari E, Katopodis K, Siamopoulos KC, Tsolas O: Paraquat-induced renal injury studied by 1H nuclear magnetic resonance spectroscopy of urine. Clin Chem 1998; 44: 1256-1261.
42. Lang DH, Yeung CK, Peter RM, et al: Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochem Pharmacol 1998; 56: 1005-1012.
43. Podadera P, Sipahi AM, Areas JA, Lanfer- Marquez UM: Diagnosis of suspected trimethylaminuria by NMR spectroscopy. Clin Chim Acta 2005; 351: 149-154.
44. Gartland KP, Bonner FW, Nicholson JK: Investigations into the biochemical effects of region-specific nephrotoxins. Mol Pharmacol 1989; 35: 242-250.
45. Anthony ML, Beddell CR, Lindon JC, Nicholson JK: Studies on the comparative toxicity of S-(1,2-dichlorovinyl)- L -cysteine, S-(1,2- dichlorovinyl)- L -homocysteine and 1,1,2- trichloro-3,3,3-trifluoro-1-propene in the Fischer 344 rat. Arch Toxicol 1994; 69: 99-110.
46. Serkova N, Hausen B, Berry GJ, Jacobsen W, Benet LZ, Morris RE, Christians U: Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZRAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine.J Pharmacol Exp Ther 2000; 294: 323-332.
47. Chapman U, O'Connell PJ, Nankivell BJ: Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015-3026.